Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

Why is Amazon cutting 14,000 corporate jobs? How will Trump’s rare earths deal impact US-Japan trade? What caused PayPal’s stock to surge today? Why did UnitedHealth raise its 2025 profit forecast? How is the Fed’s upcoming rate cut expected to affect markets? What factors led to HSBC’s recent profit decline? Why are bitcoin and crypto prices fluctuating now?

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

novartis.com/news/media-releases/novartis-agrees-acquire-avidity-biosciences-innovator-rna-therapeutics-strengthening-its-late-stage-neuroscience-pipeline

Ad hoc announcement pursuant to Art. 53 LR
- Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseases
- Advances the Novartis xRNA strategy by adding a scientifically robust, muscle-directed, Antibody…

This story appeared on novartis.com, 2025-10-27 00:43:37.591000.